Trials / Not Yet Recruiting
Not Yet RecruitingNCT07527325
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fianlimab | Given IV |
| DRUG | Cemiplimab | Given IV |
Timeline
- Start date
- 2026-04-30
- Primary completion
- 2029-02-01
- Completion
- 2030-02-01
- First posted
- 2026-04-14
- Last updated
- 2026-04-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07527325. Inclusion in this directory is not an endorsement.